IP Library Patent Application 15650656
Patent Application
App. No. 15/650,656

Methods for Development and Use of Minimally Polarized Function Cell Micro-Aggregate Units in Tissue Applications Using LGR4, LGR5, and LGR6 Expressing Epithelial Stem Cells

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/650,656
Abstract

Provided herein are constructs of micro-aggregate multicellular, minimally polarized grafts containing Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical/therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications which preferably are associated with a delivery vector/substrate/support/scaffold for direct application.

Claims (33)

1 . A minimally polarized micro-aggregate multi-cellular composition, comprising: a multi-dimensional support selected from the group consisting of scaffolding, collagen, matrix, particle, and fiber, and isolated living LGR expressing cells.

2 . The composition of claim 1 further including growth factors and the LGR expressing cells being selected from the group consisting of LGR4, LGR5 and LGR6.

3 . The composition of claim 1 further including migratory/recruiting analytes and the LGR expressing cells being selected from the group consisting of LGR4, LGR5 and LGR6.

4 . The composition according to of claim 1 further including LGR specific binding elements selected from the group consisting of ligand families, R-spondin, EDGF, PDGF, Wnt, VEGF, and antimicrobial peptides and where the LGR expressing cells are selected from the group consisting of LGR4, LGR5 and LGR6.

5 . A composition according to claim 1 where the composition is used for a therapeutic construct for any one of a tissue region, wound, void, defect tissue, or blood.

6 . A composition according to claim 1 where the composition is used as a therapeutic construct for alteration of surrounding adjacent tissues.

7 . A composition according to claim 1 where the multi-dimensional support and isolated living LGR expressing cells providing a micro-aggregate multi-cellular construct for accelerated healing of wounds.

8 . A composition according to claim 1 where the multi-dimensional support and isolated living LGR expressing cells providing a micro-aggregate multi-cellular construct for tissue system repair or restoration throughout the body.

9 . A tissue graft comprising a composition according claim 1 for application to ectodermal, mesodermal or endodermal-derived tissues systems throughout a mammalian body.

10 - 24 . (canceled)

25 . The composition according to claim 3 further including LGR specific binding elements selected from the group consisting of ligand families, R-spondin, EDGF, PDGF, Wnt, VEGF, and antimicrobial peptides and where the LGR expressing cells are selected from the group consisting of LGR4, LGR5 and LGR6.

26 . A composition according to claim 3 where the composition is used for a therapeutic construct for any one of a tissue region, wound, void, defect tissue, or blood.

27 . A composition according to claim 3 where the composition is used as a therapeutic construct for alteration of surrounding adjacent tissues.

28 . A composition according to claim 3 where the multi-dimensional support and isolated living LGR expressing cells providing a micro-aggregate multi-cellular construct for accelerated healing of wounds.

29 . A composition according to claim 3 where the multi-dimensional support and isolated living LGR expressing cells providing a micro-aggregate multi-cellular construct for tissue system repair or restoration throughout the body.

30 . A tissue graft comprising a composition according to claim 3 for application to ectodermal, mesodermal or endodermal-derived tissues systems throughout a mammalian body.

31 . A composition according to claim 4 further characterized in that the composition is used for a therapeutic construct for any one of a tissue region, wound, void, defect tissue, or blood.

32 . A composition according to claim 4 further characterized in that the composition is used as a therapeutic construct for alteration of surrounding adjacent tissues.

33 . A composition according to claim 4 further characterized by the multi-dimensional support and isolated living LGR expressing cells providing a micro-aggregate multi-cellular construct for accelerated healing of wounds.

34 . A composition according to claim 4 further characterized by the multi-dimensional support and isolated living LGR expressing cells providing a micro-aggregate multi-cellular construct for tissue system repair or restoration throughout the body.

35 . A tissue graft comprising a composition according to claim 4 for application to ectodermal, mesodermal or endodermal-derived tissues systems throughout a mammalian body.

36 - 37 . (canceled)

38 . A composition comprising mammalian epithelial tissue, wherein the mammalian epithelial tissue is minimally polarized and comprises (i) epithelial stem cells expressing LGR and (ii) supportive cellular entities.

39 . The composition of claim 38 , wherein the LGR is selected from the group consisting of LGR4, LGR5, LGR6 or combinations thereof.

40 . The composition of claim 38 , wherein the supportive cellular entities are selected from the group consisting of cellular progenitor populations, stem cell populations, extracellular matrix elements, scaffolding elements, or combinations thereof.

41 . The composition of claim 38 , where in the epithelial stem cells are provided in the form of at least a portion of at least one follicular bulge.

42 . The composition of claim 38 , wherein the epithelial stems cells are provided in the form of a skin specimen comprising at least a portion of at least one follicular bulge and epidermal, dermal, and hypodermal tissue.

43 . The composition of claim 38 , further comprising one or more supplements selected from the group consisting of growth factors, analytes, LGR specific binding elements, or combinations thereof.

44 . The composition of claim 38 , further comprise an analyte selected from the group consisting of migratory analytes, recruiting analytes, or combinations thereof.

45 . The composition of claim 38 , further comprising a LGR specific binding element selected from the group consisting of ligand families, R-spondin, EDGF, PDGF, Wnt, VEGF, antimicrobial peptides, or combinations thereof.

46 . The composition of claim 38 , wherein the composition is capable of assembling a functional polarized tissue when transplanted to a target site.

47 . A pharmaceutical composition comprising the composition of claim 38 and a deliverable vehicle.

48 . A pharmaceutical composition comprising the composition of claim 38 and a multidimensional support.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2020
From: LOUGH, DENVER M., DR.
To: POLARITYTE, INC.
Reel/Frame 052837/0544 →